Overview Safety and Efficacy of USB002 for Respiratory Distress Due to COVID-19 Status: Recruiting Trial end date: 2022-03-01 Target enrollment: Participant gender: Summary This trial will study the use of USB002 given as an intravenous infusion in patients with respiratory distress due to infection with COVID-19. Phase: Phase 2 Details Lead Sponsor: US Biotest, Inc.